SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Essential Therapeutics (ETRX) formerly Microcide (MCDE

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (305)10/30/2000 11:49:12 AM
From: scaram(o)uche  Read Replies (1) of 415
 
Motorola's Clinical Micro Sensors Unveils eSensor(TM) DNA Detection Technology At Chips To Hits Conference


The eSensor(TM) System Provides a Practical Lab Based Solution for Rapid,
Cost-Effective DNA Analysis in Medicine and Industry

PASADENA, Calif., Oct. 30 /PRNewswire/ -- Clinical Micro Sensors (CMS), a
business unit of Motorola, Inc., (NYSE: MOT), will unveil commercial versions
of its eSensor(TM) DNA detection system and demonstrate its ability to do DNA
testing relevant to healthcare, agriculture, food safety, animal health and
breeding, or environmental monitoring.
eSensor(TM) technology represents a futuristic advance in DNA analysis
with the potential to lower the cost, improve the quality, and speed-the-time
to market of DNA tests. The technology has been shown effective in studies
detecting panels of bacterial or viral targets, genetically modified crops
(GMOs), and SNPs (single nucleotide polymorphisms), the most common form of
genetic mutation in human, plants, and animals.
The eSensor(TM) system relies on bioelectronics, a major advance in DNA
analysis that will broaden the use of DNA tests to allow improved health and
safety. Bioelectronics uses organic molecules to form electronic circuit
elements that detect and quantify many different DNA and RNA targets at once.
The ability to offer a panel of tests, producing clear, unambiguous results,
will reduce the cost and increase the sophistication of practical DNA testing.
CMS expects manufacturing and shipping the first benchtop eSensor(TM)
instruments during the second quarter of 2001 for research and nonhuman
diagnostics markets such as agriculture and animal health and breeding. In
the future, CMS intends to deliver its technology for use in clinical
laboratories, point-of-care settings, and physician offices.
CMS will demonstrate eSensor(TM) DNA detection technology at International
Business Communications' (IBC) Annual Biochip Technologies Conference, Chips
To Hits, on Tuesday, November 7, 2000 at the Philadelphia Marriott Downtown in
Philadelphia, Pennsylvania. IBC's Chips To Hits event has continually grown
to become the largest annual gathering for chip technologies in the
pharmaceutical and biotechnology industries. More information regarding CMS'
demonstration at the Chips To Hits conference is available at
microsensor.com.

About Motorola
Motorola, Inc. is a global leader in providing integrated communications
solutions and embedded electronic solutions. Sales in 1999 were
$33.1 billion. Additional corporate information is available at
motorola.com.
Clinical Micro Sensors, a division of Motorola, is a leader in the field
of mass applied genomics -- the widespread application of genetic knowledge to
medicine and industry. CMS is developing DNA detection units and disposable
biochip cartridges, combining universal platform design and advanced
bioelectronic technology. The CMS eSensor(TM) system is poised to set new
standards for rapid, cost-effective DNA analysis in healthcare, agriculture,
food safety, animal health and breeding, and environmental monitoring.

Motorola and the Motorola logo are registered trademarks of Motorola, Inc.

SOURCE Clinical Micro Sensors
Web Site: microsensor.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext